The Use of Intravitreal Aflibercept in the Treatment of Wet Type of Age Related Macular Degeneration

Abstract

Aflibercept, an anti vascular endothelial growth factor (anti-VEGF) which is originally developed in the treatment of large bowel cancers, has been found to be effective in the treatment of wet ARMD, a potentially sight threatening condition affecting the back of the eye. Chemically this biological drug is C4318 H6788 N1164 O1304 S12 with a molecular weight of 96.9 KDa. This is manufactured as a lipid soluble recombinant fusion glycoprotein that binds with both forms of vascular endothelial growth factors, ie. A and B as well as placental growth factors thus blocking the angiogenic action and consequent neovascular membrane growth, the pathognomonic feature of wet ARMD.